Phio Pharmaceuticals CEO Robert J. Bitterman forfeited 68,550 shares at $1.03 per share on September 11, leaving him with 362,871 shares. The transaction represented about 15.9% of his prior shareholding, giving investors a precise measure of the change in his direct ownership.
Key Highlights
- The transaction was classified under SEC code F, which denotes tax-related withholding.
- Robert J. Bitterman held 362,871 Phio Pharmaceuticals shares after the transaction.
- The forfeited shares represented about 15.9% of his prior shareholding.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) Chairman, President and CEO Robert J. Bitterman forfeited 68,550 shares at $1.03 per share on September 11, 2026.
Bitterman Owned 362,871 Shares
Bitterman held 362,871 shares after the transaction. His listed roles at Phio Pharmaceuticals Corp. are chairman, president and CEO. The transaction was recorded using SEC transaction code F, a classification for tax-related withholding. The forfeited shares represented about 15.9% of Bitterman’s prior shares holding.
FAQs
Q: What happened to Phio Pharmaceuticals CEO Robert J. Bitterman’s shares?
A: Robert J. Bitterman forfeited 68,550 Phio Pharmaceuticals shares at $1.03 per share on September 11, 2026. The filing identifies the transaction as a forfeiture.
Q: How many PHIO shares did Bitterman own after the transaction?
A: Bitterman’s reported post-transaction balance was 362,871 Phio Pharmaceuticals shares. The filing identifies him as the company’s chairman, president and CEO.
Q: What does transaction code F mean for the PHIO share transaction?
A: SEC transaction code F identifies tax-related withholding in the reported share transaction. The forfeiture represented about 15.9% of Bitterman’s prior shares holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.